
    
      A Phase 1, Open-Label Safety and Pharmacodynamic Study of RV 001, an Insulin-Like Growth
      Factor-1 Receptor (IGF-1) Antagonist, Given By IV Infusion in Patients with Diabetic Macular
      Edema (DME).
    
  